- Home
- STTK
STTK
Shattuck Labs Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $3.00 | AVG Volume (30 days): | 108.0K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $11.76 | Next Earning Date: | 03-27-2025 |
| Revenue: | $5,721,000 | Revenue Growth: | 245.26% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Shattuck Labs Inc. News
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
GlobeNewswire
4 days ago
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
MT Newswires
14 days ago
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target
Simply Wall St.
20 days ago
Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock
GlobeNewswire
a month ago
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewswire
2 months ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
GlobeNewswire
2 months ago
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Simply Wall St.
2 months ago
Planet Image International Leads 3 US Penny Stocks To Consider
Compare STTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.